Article Details
Retrieved on: 2025-02-13 13:12:02
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the MedTech focus of Johnson & Johnson on nipocalimab, a monoclonal antibody targeting the neonatal Fc receptor to treat autoimmune diseases. It highlights its significant IgG reduction capabilities relevant to immunology and transfusion medicine. Tags like 'Antibodies', 'Neonatal fragment crystallizable receptor', and 'Hemolytic disease of the newborn' relate directly to the specifics of nipocalimab and its therapeutic potentials explored by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
Article found on: innovativemedicine.jnj.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here